The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 receptor agonists and, more recently, the dual GIP and GLP-3 receptor agonist https://shaniavxvo160212.blog5.net/87871840/glp-3-retatrutide-a-comparative-analysis